Inhibitors of c-jun-N-terminal kinase (JNK).
Inhibitors of c-jun-N-Terminal Kinase (JNK) have many potential therapeutic indications ranging from neurodegenerative disease, to metabolic disorders, inflammation, cardiovascular disease, and cancer. This overview will highlight biological inhibitors such as JNK-interacting protein (JIP) as well as small molecule inhibitors from various structural classes including, aminopyrimidines and indazoles.
LoGrasso
Philip
P
Department of Molecular Therapeutics and Drug Discovery, The Scripps Research Institute, 5353 Parkside Drive, Jupiter, FL 33458, USA. lograsso@scripps.edu
Kamenecka
Theodore
T
D000818:Animals; D006801:Humans; D048031:JNK Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000737:chemistry* / Q000494:pharmacology*; D011725:Pyridines / Q000737:chemistry / Q000494:pharmacology; D011804:Quinolines / Q000737:chemistry / Q000494:pharmacology; D013329:Structure-Activity Relationship
D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011804:Quinolines; C037219:quinoline; D048031:JNK Mitogen-Activated Protein Kinases; C023666:pyridine